Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler
- PMID: 3130088
- DOI: 10.1016/0007-0971(87)90186-0
Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler
Abstract
Sodium cromoglycate deposition has been studied following delivery of the drug by inhalation to six normal volunteers and two groups of ten patients using the Spinhaler. Plasma concentrations of the drug, and its urinary excretion have been related to the inhalation technique used for its delivery. An early peak concentration of sodium cromoglycate occurred in the plasma, thereafter the plasma concentration declined mono- or bi-exponentially with a terminal T1/2 of approximately 100 minutes in both patients and normal subjects. There was a marked between-subject variability in the plasma concentrations of sodium cromoglycate achieved, and in the areas under the plasma concentration-time curves of the drug. This reflects the variability between subjects in the amount of drug delivered to the respiratory tract. Most of this variability was due to differences in inhalation technique particularly with regard to inspiratory flow rate achieved and duration of breath-holding after inhalation. Thus careful instruction of patients is required to derive optimal dosing with sodium cromoglycate. It is recommended that patients inhale through the Spinhaler as rapidly as possible and then breath-hold for 10 seconds. These data provide a valuable background against which to study the relationship between the disposition of sodium cromoglycate, its site of action and its efficacy.
Similar articles
-
Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma.Eur Respir J. 1988 Dec;1(10):896-901. Eur Respir J. 1988. PMID: 3147196 Clinical Trial.
-
Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique.J Pharmacol Exp Ther. 1987 Jun;241(3):1028-32. J Pharmacol Exp Ther. 1987. PMID: 3110405
-
Relative lung bioavailability of generic sodium cromoglycate inhalers used with and without a spacer device.Pulm Pharmacol Ther. 2001;14(2):129-33. doi: 10.1006/pupt.2001.0279. Pulm Pharmacol Ther. 2001. PMID: 11273794 Clinical Trial.
-
Have inadequate delivery systems hampered the clinical success of inhaled disodium cromoglycate? Time for reconsideration.Expert Opin Drug Deliv. 2011 Jan;8(1):1-17. doi: 10.1517/17425247.2010.542141. Expert Opin Drug Deliv. 2011. PMID: 21174604 Review.
-
[Indication and effect of inhaled DSCG for the treatment of adult asthmatics].Nihon Rinsho. 1996 Nov;54(11):3023-8. Nihon Rinsho. 1996. PMID: 8950948 Review. Japanese.
Cited by
-
Particle size selection device for use with the Turbohaler.Thorax. 1996 May;51(5):537-9. doi: 10.1136/thx.51.5.537. Thorax. 1996. PMID: 8711685 Free PMC article.
-
Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect.Pharm Res. 1999 Jun;16(6):828-34. doi: 10.1023/a:1018865717374. Pharm Res. 1999. PMID: 10397601
-
Deposition and effects of inhaled corticosteroids.Clin Pharmacokinet. 2003;42(6):529-44. doi: 10.2165/00003088-200342060-00003. Clin Pharmacokinet. 2003. PMID: 12793838 Review.
-
The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.Pharm Res. 2017 Mar;34(3):507-528. doi: 10.1007/s11095-016-2050-x. Epub 2016 Oct 13. Pharm Res. 2017. PMID: 27738953 Review.
-
Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?Br J Clin Pharmacol. 2000 Jun;49(6):529-37. doi: 10.1046/j.1365-2125.2000.00106.x. Br J Clin Pharmacol. 2000. PMID: 10848716 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources